Hess Nicholas R, Hickey Gavin W, Keebler Mary E, Huston Jessica H, McNamara Dennis M, Mathier Michael A, Wang Yisi, Kaczorowski David J
Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania.
J Heart Lung Transplant. 2023 Jan;42(1):76-86. doi: 10.1016/j.healun.2022.08.020. Epub 2022 Sep 9.
Since the revision of the United States heart allocation system, increasing use of mechanical circulatory support has been observed as a means to support acutely ill patients. We sought to compare outcomes between patients bridged to orthotopic heart transplantation (OHT) with either temporary (t-LVAD) or durable left ventricular assist devises (d-LVAD) under the revised system.
The United States Organ Network database was queried to identify all adult OHT recipients who were bridged to transplant with either an isolated t-LVAD or d-LVAD from 10/18/2018 to 9/30/2020. The primary outcome was 1-year post-transplant survival. Predictors of mortality were also modeled, and national trends of LVAD bridging were examined across the study period.
About 1,734 OHT recipients were analyzed, 1,580 (91.1%) bridged with d-LVAD and 154 (8.9%) bridged with t-LVAD. At transplant, the t-LVAD cohort had higher total bilirubin levels and greater prevalence of pre-transplant intravenous inotrope usage and mechanical ventilation. Median waitlist time was also shorter for t-LVAD. At 1 year, there was a non-significant trend of increased survival in the t-LVAD cohort (94.8% vs 90.1%; p = 0.06). After risk adjustment, d-LVAD was associated with a 4-fold hazards for 1-year mortality (hazard ratio 3.96, 95% confidence interval 1.42-11.03; p = 0.009). From 2018 to 2021, t-LVAD bridging increased, though d-LVAD remained a more common bridging strategy.
Since the 2018 allocation change, there has been a steady increase in t-LVAD usage as a bridge to OHT. Overall, patients bridged with these devices appear to have least equivalent 1-year survival compared to those bridged with d-LVAD.
自美国心脏分配系统修订以来,机械循环支持作为支持急性病患者的一种手段,其使用量一直在增加。我们试图比较在修订后的系统下,使用临时左心室辅助装置(t-LVAD)或耐用左心室辅助装置(d-LVAD)过渡到原位心脏移植(OHT)的患者之间的结局。
查询美国器官网络数据库,以识别2018年10月18日至2020年9月30日期间,所有使用单独的t-LVAD或d-LVAD过渡到移植的成年OHT受者。主要结局是移植后1年生存率。还对死亡率的预测因素进行了建模,并研究了整个研究期间LVAD过渡的全国趋势。
共分析了约1734名OHT受者,其中1580名(91.1%)使用d-LVAD过渡,154名(8.9%)使用t-LVAD过渡。在移植时,t-LVAD队列的总胆红素水平较高,移植前静脉使用血管活性药物和机械通气的发生率也较高。t-LVAD队列的中位等待时间也较短。1年时,t-LVAD队列的生存率有增加的趋势,但无统计学意义(94.8%对90.1%;p = 0.06)。风险调整后,d-LVAD与1年死亡率的风险增加4倍相关(风险比3.96,95%置信区间1.42-11.03;p = 0.009)。从2018年到2021年,t-LVAD过渡有所增加,尽管d-LVAD仍然是更常见的过渡策略。
自2018年分配变化以来,t-LVAD作为OHT过渡手段的使用量稳步增加。总体而言,与使用d-LVAD过渡的患者相比,使用这些装置过渡的患者1年生存率似乎至少相当。